Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma

Oss, The Netherlands (ots/PRNewswire) - Organon, the humanhealthcare business unit of Akzo Nobel, today announced that it hassigned an exclusive, worldwide license agreement with Endotis Pharmaconcerning the development and commercialization of severalantithrombotic compounds. Endotis is a specialty pharma companydedicated to the discovery and development of small-glyco drugs forapplications in thrombosis and oncology.

Under the terms of the agreement, Endotis has acquired exclusiverights to develop and commercialize Org 42675, Org 217609 (aneutralizable follow-up of Org 42675) and Org 224283, threeantithrombotic compounds with an innovative dual mechanism of action.Financial details are not disclosed.

Org 42675 and Org 217609 display a new and original dual mechanismof action, combining blood coagulation factor Xa inhibition andthrombin inhibition. Org 42675 has successfully completed two phase Iclinical trials. Org 224283 also displays an innovative dualmechanism of action, combining factor Xa inhibition and anantiplatelet effect, both effects being neutralizable by a specificantidote. Org 224283 is at a preclinical-stage of development.

Charles Woler, Chairman and CEO of Endotis Pharma, declared: "Weare delighted to sign this licensing agreement, as these compoundswill strongly reinforce our position in thrombosis. Due to theiroligosaccharide structure, they perfectly fit with our focus onsmall-glyco drugs. We are proud that Organon has faith in Endotis todevelop these very promising compounds."

David Nicholson, executive vice president Research and Developmentof Organon added: "We are excited to bring this opportunity toEndotis. Organon will continue to be involved bringing in ourexpertise in manufacturing and development. This deal maximizes thechances of bringing these innovative compounds to patients in need ofanti-thrombotic care."

About Organon

Organon creates, manufactures and markets innovative prescriptionmedicines that improve the health and quality of human life. Througha combination of innovation and business partnerships, Organon seeksto leverage its position as a leading biopharmaceutical company ineach of its core therapeutic fields: fertility, gynecology andselected areas of anesthesia. It has extensive expertise inneuroscience and a rich and focused R&D program. Research areas alsoinclude immunology and specific areas of oncology. Organon productsare distributed in over 100 countries worldwide, of which more than50 have an Organon subsidiary. Organon is the human healthcarebusiness unit of Akzo Nobel.

About Endotis Pharma

Founded in 2003, Endotis Pharma is a specialty pharma companydedicated to the discovery and development of small-glyco drugs(SGDs) for applications in thrombosis and oncology. Endotis Pharmahas built a well-balanced portfolio of pre-clinical and clinicalstage compounds, either in-licensed (from Organon: EP42675, ananticoagulant that has completed two phase I, EP217609, theneutralizable form of EP4675 and EP224283, an antithrombotic which isin preclinicals) or generated by the company's own drug discoveryplatform (EP37 program, focused on the oral prevention and treatmentof thrombosis, and EP8000 program in oncology). The SGDs developed byEndotis are based on fully synthetic oligosaccharides mimickingglycosaminoglycans, which is the core field of expertise of Endotis'scientists. Proof of concept has already been established withsynthetic oligosaccharides in cardiovascular/thrombosis, withoncology being the next promising therapeutic area. Endotis currentlyhas 28 employees (including 14 PhDs/MDs) based in Paris and Lille(France). Sofinnova Partners is a lead investor in Endotis Pharma.

Disclaimer: the development of new drug technologies is difficult,erratic and unpredictable. Endotis Pharma's forecasts and futureeconomic performance depend on research that has yet to be performedand on a number of other factors. The company's future economicperformance may differ significantly from that currently forecast.

Safe Harbor Statement Organon(1)

This press release may contain statements which address such keyissues as Akzo Nobel's growth strategy, future financial results,market positions, product development, pharmaceutical products in thepipeline, and product approvals. Such statements should be carefullyconsidered, and it should be understood that many factors could causeforecasted and actual results to differ from these statements. Thesefactors include, but are not limited to, price fluctuations, currencyfluctuations, progress of drug development, clinical testing andregulatory approval, developments in raw material and personnelcosts, pensions, physical and environmental risks, legal issues, andlegislative, fiscal, and other regulatory measures. Statedcompetitive positions are based on management estimates supported byinformation provided by specialized external agencies. For a morecomprehensive discussion of the risk factors affecting our businessplease see our Annual Report on Form 20-F filed with the UnitedStates Securities and Exchange Commission, a copy of which can befound on the company's corporate website http://www.akzonobel.com.The 2006 Annual Report on Form 20-F will be available in the secondquarter of 2007.

(1) Pursuant to the U.S. Private Securities Litigation Reform Act1995.

For more information: Organon Monique Mols, director media relations NV Organon, Oss, the Netherlands Tel: +31-412-665440 Email: monique.mols@organon.com Endotis Pharma: Press: Alize RP Caroline Carmagnol +33(0)6-64-18-99-5 caroline@alizerp.com Investors: Endotis Pharma Charles Woler, Chairman and CEO charleswoler@endotis.com Stéphane Degove , Finance Director stephanedegove@endotis.com +33(0)-1-48-46-84-87

ots Originaltext: N.V. OrganonIm Internet recherchierbar: http://www.presseportal.de

Contact:For more information: Organon, Monique Mols, director media relations, NV Organon, Oss, The Netherlands, Tel: +31-412-665440, Email: monique.mols@organon.com; Endotis Pharma: Press: Alize RP, Caroline Carmagnol, +33(0)6-64-18-99-5, caroline@alizerp.com; Investors: Endotis Pharma, Charles Woler, Chairman and CEO, charleswoler@endotis.com, Stéphane Degove, Finance Director, stephanedegove@endotis.com, +33(0)-1-48-46-84-87

N.V. Organon

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


Organon Signs an Exclusive, Worldwide Licence Agreement on Advanced Antithrombotic Compounds With Endotis Pharma